GPhA announces executive committee, board of directors

ORLANDO, Fla. — The Generic Pharmaceutical Association has elected its 2011 executive committee and board of directors, the generic drug industry trade group announced. As part of a reorganization last year, the board has been reduced to 12 members.

The GPhA said Watson Pharmaceuticals president and CEO Paul Bisaro had been reelected as chairman for a second, one-year term. Also elected were Mylan Pharmaceuticals president Tony Mauro, as vice chairman; and Momenta Pharmaceuticals president Craig Wheeler, as secretary treasurer.

Other members of the board of directors are Teva Pharmaceuticals USA SVP government affairs Debra Barrett; Actavis president and CEO Doug Boothe; Ranbaxy VP corporate communications and government affairs Chuck Caprariello; Sandoz president and CEO Don DeGolyer; Fougera SVP and general manager David Klaum; Par Pharmaceutical president and CEO Patrick LePore; Ben Venue Labs president and CEO Tom Murphy; Zydus Pharmaceuticals USA president and CEO Joseph Renner; APP Pharmaceuticals president and CEO Tom Silberg.

The GPhA’s executive committee is comprised of Bisaro, Mauro, Wheeler, Barrett, Boothe, DeGolyer and Klaum.

“We enter 2011 as a stronger organization, with renewed vigor, a sharper focus and an appreciation of the power that a single, unified voice can have,” Bisaro said. “Equally as important, we start 2011 with the resources — financial, intellectual and structural — to get the job done.”